Skip to main
GENB

GENB Stock Forecast & Price Target

GENB Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Generate Biomedicines is poised for success due to its innovative approach to drug discovery through AI, a strong pipeline of promising candidates including a twice-yearly dosing drug for severe asthma, partnerships with reputable institutions and potential collaborations with major pharmaceutical companies, and a solid financial position with potential for significant milestones and royalties.

Bears say

Generate Biomedicines is heavily reliant on its AI-generated platform for drug discovery and development, but the platform has yet to produce a defining clinical success. Additionally, its lead product candidate, GB-0895, faces competition from an established, well-reimbursed standard of care for severe asthma, and there are concerns about potential supply chain disruptions from regulatory compliance changes. The company also has a high cash burn rate and may need to raise additional capital in the future to fund operations, which could pose a risk to its financial stability.

GENB has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Generate Biomedicines Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Generate Biomedicines Inc (GENB) Forecast

Analysts have given GENB a Strong Buy based on their latest research and market trends.

According to 5 analysts, GENB has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Generate Biomedicines Inc (GENB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.